Radiopharmaceutical enhancement by drug delivery systems : a review

Show simple item record

dc.contributor.author Kleynhans, Janke
dc.contributor.author Grobler, Anne Frederica
dc.contributor.author Ebenhan, Thomas
dc.contributor.author Sathekge, Mike Machaba
dc.contributor.author Zeevaart, Jan-Rijn
dc.date.accessioned 2018-09-13T10:47:38Z
dc.date.issued 2018-10
dc.description.abstract INTRODUCTION : Drug delivery systems are entities designed to alter the biological behaviour of the pharmaceutical active ingredients that they carry in order to afford more beneficial biodistribution and safety profiles. Many problems currently faced by the field of nuclear medicine (e.g. developing new theranostic agents, utilizing multimodal imaging platforms and providing targeted delivery) can be facilitated by applying drug delivery systems to radiopharmaceuticals that have been proven successful in other medical fields. This review describes the advancements being made towards this goal. AREAS COVERED : All aspects of drug delivery systems (liposomes, nanoparticles, microspheres) in the field of nuclear medicine are discussed. Only systems with foreseen or confirmed clinical applications in nuclear medicine are discussed, not instances where nuclear imaging is merely a tool to evaluate the biodistribution of novel delivery technologies. CONCLUSIONS : Great advancements have been made with the development of novel systems incorporating nuclear entities in drug delivery systems, with the possibility of reshaping the nuclear medicine landscape. Nonetheless, translation from preclinical evaluations to clinical use is lacking and serious investment needs to be made towards this goal. en_ZA
dc.description.department Nuclear Medicine en_ZA
dc.description.embargo 2019-10-10
dc.description.librarian hj2018 en_ZA
dc.description.sponsorship J. Kleynhans received financial assistance from the National Research Foundation (NRF) of South Africa (grant number SFH 14070573914) as well as the Nuclear Technologies in Medicine and Biosciences Initiative (NTeMBI)- a national technology platform developed and managed by the South African Nuclear Energy Corporation (Necsa) and funded by the Department of Science and Technology. en_ZA
dc.description.uri http://www.elsevier.com/locate/jconrel en_ZA
dc.identifier.citation Kleynhans, J., Grobler, A.F., Ebenhan, T. et al. 2018, 'Radiopharmaceutical enhancement by drug delivery systems : a review', Journal of Controlled Release. vol. 287, pp. 177-193. en_ZA
dc.identifier.issn 0168-3659 (print)
dc.identifier.issn 1873-4995 (online)
dc.identifier.other 10.1016/j.jconrel.2018.08.008
dc.identifier.uri http://hdl.handle.net/2263/66558
dc.language.iso en en_ZA
dc.publisher Elsevier en_ZA
dc.rights © 2018 Elsevier B.V. All rights reserved. Notice : this is the author’s version of a work that was accepted for publication in Journal of Controlled Release. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. A definitive version was subsequently published in Journal of Controlled Release, vol. 287, pp. 177-193, 2018. doi : 10.1016/j.jconrel.2018.08.008. en_ZA
dc.subject Drug carrier systems en_ZA
dc.subject Multi-modality imaging en_ZA
dc.subject Nuclear medicine en_ZA
dc.subject Radiopharmaceuticals en_ZA
dc.subject Theranostics en_ZA
dc.subject Controlled drug delivery en_ZA
dc.subject Drug delivery system en_ZA
dc.subject Clinical application en_ZA
dc.subject Active ingredients en_ZA
dc.subject Targeted drug delivery en_ZA
dc.subject Medical problems en_ZA
dc.subject Medical imaging en_ZA
dc.subject Liposomes en_ZA
dc.title Radiopharmaceutical enhancement by drug delivery systems : a review en_ZA
dc.type Postprint Article en_ZA


Files in this item

This item appears in the following Collection(s)

Show simple item record